Aichi M6A

The V Foundation for Cancer Research Announces the First Class of A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research

Retrieved on: 
Tuesday, June 27, 2023
Pancreatic cancer, Tobacco Products Scientific Advisory Committee, VCU Massey Cancer Center, Male, University, Mohammed V Foundation for Solidarity, Cancer research, COVID-19, NYU, Cancer, Jim Valvano, CDK7, Woman, Research, Salk Institute for Biological Studies, RNA, Assistant, Science, Cooper University Hospital, UCSF, Patient, Cancer Treatment Centers of America, Engineering, Melanoma, Dartmouth Cancer Center, Washington University School of Medicine, University of British Columbia, Ovarian cancer, Aichi M6A, Female, Prostate cancer, Dana–Farber Cancer Institute, Pharmaceutical industry, Nursing, Vaccine, Birth control, Doctor of Philosophy, MD

CARY, N.C., June 27, 2023 /PRNewswire/ -- The V Foundation for Cancer Research, a premier cancer research charity, proudly announces the first recipients of A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research. This landmark initiative is helping to counteract longstanding gender disparities in research by investing $8 million in the groundbreaking work of 11 women scientists leading the charge in cancer research.

Key Points: 
  • CARY, N.C., June 27, 2023 /PRNewswire/ -- The V Foundation for Cancer Research, a premier cancer research charity, proudly announces the first recipients of A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research.
  • We are not only advancing vital cancer research, but we're working to encourage more women to pursue careers in science.
  • The setbacks endured throughout the pandemic will have long-term for women in cancer research.
  • Recognizing these disparities, the V Foundation for Cancer Research developed A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research to amplify female representation and encourage more women-led breakthroughs in this field.

Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3

Retrieved on: 
Monday, October 18, 2021
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, American Cancer Society, Risk, Methylation, Cell, Incidence, ADR, Blood, Cancer, Hematological Cancer Research Investment and Education Act, Senior, Heart, AML, Growth, Accent, RNA transfection, Protein, Therapy, RMP, METTL14, McNeil Consumer Healthcare, METTL3, RNA, Development, Neglected tropical disease research and development, Clinical trial, Patient, Biology, Data, Acute myeloid leukemia, Oncogene, Bone marrow, Apoptosis, SLAS Discovery, Patent, Aichi M6A, IPN, Pharmaceutical industry

Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accents pre-clinical stage METTL3 program.

Key Points: 
  • Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accents pre-clinical stage METTL3 program.
  • Christelle Huguet, Senior Vice President, Head of Research, External Innovation and Early Development, Ipsen, said Oncology is a key focus area for Ipsen as we grow our pipeline.
  • We are delighted to partner with Accent to progress the METTL3 program as we continue our expansion into hematologic oncology.
  • Accent Therapeutics novel investigational small molecule inhibitors of METTL3 seek to treat specific sub-types of AML with high unmet medical need.

SeqLL Announces Publication of a New Single-Cell Epitranscriptomic Method Powered by SeqLL’s tSMS® Platform

Retrieved on: 
Thursday, September 23, 2021
Molecule, National Human Genome Research Institute, Nature, Gene expression, RNA transfection, PCR, AML, National, Risk, RNA, NHGRI, Security (finance), Massachusetts, Hospital, NASDAQ, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, DNA, Single molecule fluorescent sequencing, User experience, Independent school district, SQL, Method, Lung cancer, Bias, CEO, Form, Company, Adenosine, Disease, Cell, Technology, Aichi M6A, Research, NIH, Forward-looking statement, Intellectual property, Doctor of Philosophy, Time, Massachusetts General Hospital, GLOBE, 3D printing, Pharmaceutical industry, Fine chemical

WOBURN, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields, today announced the peer-reviewed publication of a new microscopy-based epitranscriptomic method powered by SeqLL’s tSMS platform in the August issue of Cell Report Methods. The method was developed in collaboration with the laboratory of Bradley E. Bernstein, MD, PhD through grant R01-HG009269 from the National Institutes of Health (NIH) and the National Human Genome Research Institute (NHGRI).

Key Points: 
  • However, this platform provides multifaceted information in single cell resolution, which will be helpful for cancer diagnosis and assessing its causality.
  • Using this epitranscriptomic method to profile single cells, researchers will have the power to reveal insights into complex biological pathways beyond those that current methods allow.
  • SeqLLs exclusive True Single Molecule Sequencing (tSMS) technology enables direct sequencing of millions of individual molecules.
  • The tSMS platform offers maximum flexibility and avoids many of the challenges common for standard sequencing approaches.